GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adverum Biotechnologies Inc (NAS:ADVM) » Definitions » Cyclically Adjusted Price-to-FCF

Adverum Biotechnologies (Adverum Biotechnologies) Cyclically Adjusted Price-to-FCF : (As of Apr. 28, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Adverum Biotechnologies Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Adverum Biotechnologies Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Adverum Biotechnologies's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adverum Biotechnologies Cyclically Adjusted Price-to-FCF Chart

Adverum Biotechnologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Adverum Biotechnologies Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Adverum Biotechnologies's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Adverum Biotechnologies's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adverum Biotechnologies's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adverum Biotechnologies's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Adverum Biotechnologies's Cyclically Adjusted Price-to-FCF falls into.



Adverum Biotechnologies Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Adverum Biotechnologies's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Adverum Biotechnologies's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-2.126/129.4194*129.4194
=-2.126

Current CPI (Dec. 2023) = 129.4194.

Adverum Biotechnologies Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 -0.671 99.695 -0.871
201406 2.551 100.560 3.283
201409 -3.098 100.428 -3.992
201412 -2.382 99.070 -3.112
201503 -3.276 99.621 -4.256
201506 -4.039 100.684 -5.192
201509 -4.102 100.392 -5.288
201512 -3.613 99.792 -4.686
201603 -4.530 100.470 -5.835
201606 -2.634 101.688 -3.352
201609 -2.416 101.861 -3.070
201612 -2.215 101.863 -2.814
201703 -2.867 102.862 -3.607
201706 -2.764 103.349 -3.461
201709 -2.345 104.136 -2.914
201712 -2.667 104.011 -3.319
201803 -2.299 105.290 -2.826
201806 -1.846 106.317 -2.247
201809 -2.749 106.507 -3.340
201812 -2.048 105.998 -2.501
201903 -2.440 107.251 -2.944
201906 -2.210 108.070 -2.647
201909 -2.438 108.329 -2.913
201912 -3.564 108.420 -4.254
202003 -2.415 108.902 -2.870
202006 -2.496 108.767 -2.970
202009 -3.334 109.815 -3.929
202012 -2.424 109.897 -2.855
202103 -2.425 111.754 -2.808
202106 -3.832 114.631 -4.326
202109 -3.212 115.734 -3.592
202112 -3.070 117.630 -3.378
202203 -3.378 121.301 -3.604
202206 -3.567 125.017 -3.693
202209 -3.280 125.227 -3.390
202212 -1.867 125.222 -1.930
202303 -2.243 127.348 -2.279
202306 -2.311 128.729 -2.323
202309 -2.417 129.860 -2.409
202312 -2.126 129.419 -2.126

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Adverum Biotechnologies  (NAS:ADVM) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Adverum Biotechnologies Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Adverum Biotechnologies's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Adverum Biotechnologies (Adverum Biotechnologies) Business Description

Traded in Other Exchanges
Address
100 Cardinal Way, Redwood CIty, CA, USA, 94063
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.
Executives
C. David Nicholson, director 103 CHILDS ROAD, BASKIN RIDGE NJ 07092
Setareh Seyedkazemi officer: Chief Development Officer C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL DRIVE, REDWOOD CITY CA 94063
Linda M Rubinstein officer: Chief Financial Officer 25861 INDUSTRIAL BLVD, HAYWARD CA 94545
Peter Soparkar officer: Chief Legal Officer C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY CA 94063
Brigit Riley officer: Chief Scientific Officer 100 CARDINAL WAY, REDWOOD CITY CA 94063
Laurent Fischer director, officer: CEO and Director C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY CA 94063
Richard Beckman officer: Chief Medical Officer C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY CA 94063
Nancy E Pecota officer: Principal Accounting Officer ARADIGM CORPORATION, 3929 POINT EDEN WAY, HAYWARD CA 94545
John Rakow officer: SVP, Genl Counsel, Acting CFO C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY CA 94063
Rupert D'souza officer: Chief Financial Officer C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY CA 94063
Dawn Svoronos director C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Soo Hong director C/O ADVERUM BIOTECHNOLOGIES, INC., 800 SAGINAW DRIVE, REDWOOD CITY CA 94063
Rabia Gurses Ozden director C/O AKOUOS, INC., 645 SUMMER STREET SUITE 200, BOSTON MA 02210
James Paul Scopa director 601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Julie Clark officer: Chief Medical Officer C/O ADVERUM BIOTECHNOLOGIES, INC., 800 SAGINAW DRIVE, REDWOOD CITY CA 94063

Adverum Biotechnologies (Adverum Biotechnologies) Headlines

From GuruFocus